AstraZeneca to roll out in India multiple Covid therapies in 2022 | India News – Rashtra News : Rashtra News
#AstraZeneca #roll #India #multiple #Covid #therapies #India #News #Times #India
MUMBAI: Drug biggie AstraZeneca is stepping on the gas in the fight against the Covid-19 virus with plans to launch a next generation jab to address emerging strains, a cocktail of two monoclonal antibodies for prevention-to-treatment, and a booster shot of its existing vaccine.
The Covid therapies including the vaccines are expected to be rolled out in India next year, and could be manufactured at the Serum Institute, sources told TOI. Since these therapies are under development or under trials, final agreements are yet to be inked.
“AstraZeneca is working with governments around the world to make AZD7442 (cocktail of monoclonal antibodies) accessible to high-risk populations as another valuable option in the fight to end Covid, should it prove to be effective and well tolerated. Additionally, the new Covid-19 variant vaccine AZD2816 is under trial and once initial data becomes available, will be submitted to regulators for assessment as a next-generation booster vaccine and through an expedited regulatory pathway,” AstraZeneca India MD Gagandeep Singh told TOI.
The next generation vaccine is under trials in the UK and Brazil. The company has accelerated efforts to advance the development of the antibody cocktail — long-acting antibody combination — for potential prevention and treatment of Covid.
The Covid therapies including the vaccines are expected to be rolled out in India next year, and could be manufactured at the Serum Institute, sources told TOI. Since these therapies are under development or under trials, final agreements are yet to be inked.
“AstraZeneca is working with governments around the world to make AZD7442 (cocktail of monoclonal antibodies) accessible to high-risk populations as another valuable option in the fight to end Covid, should it prove to be effective and well tolerated. Additionally, the new Covid-19 variant vaccine AZD2816 is under trial and once initial data becomes available, will be submitted to regulators for assessment as a next-generation booster vaccine and through an expedited regulatory pathway,” AstraZeneca India MD Gagandeep Singh told TOI.
The next generation vaccine is under trials in the UK and Brazil. The company has accelerated efforts to advance the development of the antibody cocktail — long-acting antibody combination — for potential prevention and treatment of Covid.
( News Source :Except for the headline, this story has not been edited by Rashtra News staff and is published from a timesofindia.indiatimes.com feed.)